Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathalie Thelemann

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 3, 2024
GLP-1 in patients with myocardial infarction complicated by cardiogenic shock-an IABP-SHOCK II-substudyMichael Lehrke, Georg Fuernau, Christian Jung, et al.
European Heart Journal. Acute Cardiovascular Care|June 11, 2020
Impact of timing of intraaortic balloon counterpulsation on mortality in cardiogenic shock - a subanalysis of the IABP-SHOCK II trialGeorg Fuernau, Jakob Ledwoch, Steffen Desch, et al.
Circulation|December 28, 2018
Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II TrialHolger Thiele, Uwe Zeymer, Nathalie Thelemann, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 3, 2024
GLP-1 in patients with myocardial infarction complicated by cardiogenic shock-an IABP-SHOCK II-substudyMichael Lehrke, Georg Fuernau, Christian Jung, et al.
European Heart Journal. Acute Cardiovascular Care|June 11, 2020
Impact of timing of intraaortic balloon counterpulsation on mortality in cardiogenic shock - a subanalysis of the IABP-SHOCK II trialGeorg Fuernau, Jakob Ledwoch, Steffen Desch, et al.
Circulation|December 28, 2018
Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II TrialHolger Thiele, Uwe Zeymer, Nathalie Thelemann, et al.
Pageof 1